CEOP方案治疗121例非霍奇金淋巴瘤

目的分析CEOP方案治疗非霍奇金淋巴瘤（NHL）患者的近期疗效、远期生存和不良反应。方法回顾性分析121例NHL患者的临床特征及CEOP方案化疗加或不加局部放疗的近期疗效、不良反应和远期生存情况。结果121例NHL患者中,B细胞性NHL83例,占68．6％,外周T或NK细胞性NHL38例,占31．4％;中位年龄53岁;临床分期Ⅰ-Ⅱ期67例,占55．4％;国际预后指数（IPI）评分0-2分108例（89．3％）。121例患者均采用CEOP方案化疗加或不加局部放疗。121例患者均可评价客观疗效,总有效率为90．9％,CR率为71．9％。121例患者共接受CEOP方案化疗471个疗程（中位疗程数4个）,主要不良反应为骨髓抑制,其中Ⅲ-Ⅳ度粒细胞减少为11．9％,Ⅲ-Ⅳ度血小板减少为1．9％,Ⅲ-Ⅳ度贫血为1．1％;脱发46．3％,心脏毒性少见,仅占4．7％,且均为可逆性轻度心电图异常。中位随访时间63（2-116）个月,1、3和5年生存率分别为84．8％、62．7％、55．9％,中位生存期85个月（2-118个月,95％可信区间65-105个月）。结论采用CEOP方案治疗NHL近期疗效、远期生存率均较高,心脏毒性较低,值得临床进一步验证和推广应用。

CEOP regimen in the treatment for non-Hodgkin's lymphoma

OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL). METHODS: From January 1995 to December 2000, 121 patients with NHL were treated by CEOP regimen with or without radiotherapy for the involved field. The clinical characteristics, response, toxicity and long-term survival results were analysed retrospectively. RESULTS: Of these 121 patients, 83 (68.6%) had B-cell NHL and 38(31.4%) peripheral T or NK-cell NHL; 55. 4% (67/121) had early disease (stage I or II), and 89.3% (108/121) had IPI score 0-2. The median age was 53 years (range: 7-79 yr). All patients were treated by CEOP regimen (totally, 471 cycles) with or without radiotherapy. The overall response (OR) rate in this series was 90.9% (110/121) with a complete remission (CR) rate of 71.9% (87/121); whereas the response rate of chemotherapy alone was 88.4% (107/121) with a CR rate of 67.8% (82/121). Major toxicity consisted of grade III-IV myelosuppression (11.9%), neutropenia (1.9%) and thrombocytopenia and anemia (1.1%). Alopecia was observed in 46.3%. However, cardiotoxicity was mild and reversible. Median follow-up duration in this series was 63 months (range: 2-116 months). The overall 1-, 3- and 5-year survival rate was 84.8%, 62.7% and 55.9%, respectively, with a median survival time of 85 months (2-118 months). CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.